Aug 30, 2008 11:31 AM ET | Site Changes | Help
Results 1 - 10 of 108 : 1 2 3 4 5 6 7 8 9 Next
Will Biopharma Acquisitions Never Cease?
Enough already! Give us poor, weary reporters a moment to rest.
You Can't Resist This Stock Price
Go with your gut? Not so fast.
Do these funds really belong in your portfolio?
Read on to see if you have what it takes to beat the market.
PDL BioPharma's Partnership Makes Sense
Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer.
When Breaking Up Isn't Hard to Do
PDL BioPharma and Enzon look to spin off parts of their business.
Genentech Asks Roche to Pay Up
It isn't going to be taken out at $89 a share.
Technical Analysis: A Damning Verdict
This study took a close look and the results are not impressive.
Despite his tough talk, Icahn will likely complete a buyout of ImClone.
Is $60 a Share Enough for ImClone?
Another big name in biotech could be on the brink of being taken out.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK